Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
MaxCyte, Inc. (LSE: MXCT) announced the pricing of an upsized offering of 13,500,000 shares at US$13.00 each, projected to raise gross proceeds of approximately US$175.5 million. The net proceeds will support R&D, manufacturing expansions, and general corporate purposes. Trading on the Nasdaq is set to begin on July 30, 2021. Additionally, related party Casdin Partners aims to purchase 1,800,000 shares, which will give them a 14% stake post-offering. The closing of the offering is expected on August 3, 2021.